Literature DB >> 10581081

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.

L E Smith1, W Shen, C Perruzzi, S Soker, F Kinose, X Xu, G Robinson, S Driver, J Bischoff, B Zhang, J M Schaeffer, D R Senger.   

Abstract

Although insulin-like growth factor 1 (IGF-1) has been associated with retinopathy, proof of a direct relationship has been lacking. Here we show that an IGF-1 receptor antagonist suppresses retinal neovascularization in vivo, and infer that interactions between IGF-1 and the IGF-1 receptor are necessary for induction of maximal neovascularization by vascular endothelial growth factor (VEGF). IGF-1 receptor regulation of VEGF action is mediated at least in part through control of VEGF activation of p44/42 mitogen-activated protein kinase, establishing a hierarchical relationship between IGF-1 and VEGF receptors. These findings establish an essential role for IGF-1 in angiogenesis and demonstrate a new target for control of retinopathy. They also explain why diabetic retinopathy initially increases with the onset of insulin treatment. IGF-1 levels, low in untreated diabetes, rise with insulin therapy, permitting VEGF-induced retinopathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581081     DOI: 10.1038/70963

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  160 in total

Review 1.  Glucose, VEGF-A, and diabetic complications.

Authors:  L E Benjamin
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.

Authors:  Mien V Hoang; Mary C Whelan; Donald R Senger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

Review 3.  What's new in the IGF-binding proteins?

Authors:  Steven A Rosenzweig
Journal:  Growth Horm IGF Res       Date:  2004-10       Impact factor: 2.372

Review 4.  The mouse retina as an angiogenesis model.

Authors:  Andreas Stahl; Kip M Connor; Przemyslaw Sapieha; Jing Chen; Roberta J Dennison; Nathan M Krah; Molly R Seaward; Keirnan L Willett; Christopher M Aderman; Karen I Guerin; Jing Hua; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06       Impact factor: 4.799

5.  The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor.

Authors:  Cecilia A Fernandez; Roopali Roy; Sunyoung Lee; Jiang Yang; Dipak Panigrahy; Krystyn J Van Vliet; Marsha A Moses
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

6.  Expressions of survivin and vascular endothelial growth factor in a Murine model of proliferative retinopathy.

Authors:  Na Cai; Ning-Ning Liu; Ning Zhao; Chao Wan; Yue-Dong Hu; Yun Zhou; Lei Chen
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

7.  Possible involvement of IGF-1 receptor and IGF-binding protein in insulin-induced enhancement of noradrenaline response in diabetic rat aorta.

Authors:  Tsuneo Kobayashi; Akihito Kaneda; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

8.  Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.

Authors:  Jesús Ruberte; Eduard Ayuso; Marc Navarro; Ana Carretero; Víctor Nacher; Virginia Haurigot; Mónica George; Cristina Llombart; Alba Casellas; Cristina Costa; Assumpció Bosch; Fatima Bosch
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  Longitudinal study of the association between thrombocytopenia and retinopathy of prematurity.

Authors:  Anne K Jensen; Gui-Shuang Ying; Jiayan Huang; Graham E Quinn; Gil Binenbaum
Journal:  J AAPOS       Date:  2018-03-14       Impact factor: 1.220

10.  POSTNATAL SERUM INSULIN-LIKE GROWTH FACTOR I AND RETINOPATHY OF PREMATURITY.

Authors:  Anne K Jensen; Gui-Shuang Ying; Jiayan Huang; Graham E Quinn; Gil Binenbaum
Journal:  Retina       Date:  2017-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.